Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1980)	1/23/2000 6:32:00 PM
From: Slugger	Respond to of 2028

This is a few days old, but wasn't posted here: Thursday January 20, 9:38 am Eastern Time RESEARCH ALERT - Bio-Technology started NEW YORK, Jan 20 (Reuters) - Warburg Dillon Read on Thursday said analyst Michael Wood initiated coverage of Bio-Technology General Corp. (NasdaqNM:BTGC - news) with a buy. -- said company has $700 million market cap and trades at a ``substantial' discount to other profitable biotechs. -- sees EPS growth of about 20 percent over next five years. -- set price target of $18.50. -- said firm has five products on market, with two biggest expected to drive most of firm's earnings growth over next two years. -- Shares rose about 1/2 to 15-11/16 in Nasdaq trade early on Thursday.

To: Jim Oravetz who wrote (1980)	2/2/2000 1:02:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2028

Draxis Health Starts Phase III Fibrimage Trials MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX) said its Draximage Inc. radiopharmaceutical subsidiary has started Phase III clinical trials in Canada for Fibrimage, a diagnostic tool for deep vein thrombosis, or DVT. In a news release, the drug company said the trial should involve 130 patients and be completed by the end of the year. DVTs are blood clots that form in the lower limbs and can lead to a pulmonary embolism, or a blockage of blood flow to the lungs, a condition that kills about 200,000 people a year in the U.S., it said. It said Fibrimage is based on Fibrin Binding Domain, a recombinant polypeptide developed by Bio-Technology General Corp. (BTGC) and licensed to Draximage on an exclusive, worldwide basis.